A potential diagnostic biomarker: Proteasome LMP2/b1i-differential expression in human uterus neoplasm

Uterine leiomyosarcoma (ULMS) develops more often in the muscle tissue layer of the uterine body than in the uterine cervix. The development of gynecologic tumors is often correlated with female hormone secretion; however, the development of uterine ULMS is not substantially correlated with hormonal conditions, and the risk factors are not yet known. Importantly, a diagnostic-biomarker which distinguishes malignant ULMS from benign tumor leiomyoma (LMA) is yet to be established. Accordingly, it is necessary to analyze risk factors associated with uterine ULMS, to establish a treatment method. Proteasome low-molecular mass polypeptide 2(LMP2)/b1i-deficient mice spontaneously develop uterine LMS, with a disease prevalence of ~40% by 14 months of age. We found LMP2/b1i expression to be absent in human LMS, but present in human LMA. Therefore, defective-LMP2/b1i expression may be one of the risk factors for ULMS. LMP2/b1i is a potential diagnostic-biomarker for uterine ULMS, and may be a targeted-molecule for a new therapeutic approach

Measurement of redshift dependent cross correlation of HSC clusters and Fermi γ\gamma rays

The cross-correlation study of the unresolved $\gamma$-ray background (UGRB) with galaxy clusters has a potential to reveal the nature of the UGRB. In this paper, we perform a cross-correlation analysis between $\gamma$-ray data by the Fermi Large Area Telescope (Fermi-LAT) and a galaxy cluster catalogue from the Subaru Hyper Suprime-Cam (HSC) survey. The Subaru HSC cluster catalogue provides a wide and homogeneous large-scale structure distribution out to the high redshift at $z=1.1$, which has not been accessible in previous cross-correlation studies. We conduct the cross-correlation analysis not only for clusters in the all redshift range ($0.1 < z < 1.1$) of the survey, but also for subsamples of clusters divided into redshift bins, the low redshift bin ($0.1 < z < 0.6$) and the high redshift bin ($0.6 < z < 1.1$), to utilize the wide redshift coverage of the cluster catalogue. We find the evidence of the cross-correlation signals with the significance of 2.0-2.3$\sigma$ for all redshift and low-redshift cluster samples. On the other hand, for high-redshift clusters, we find the signal with weaker significance level (1.6-1.9$\sigma$). We also compare the observed cross-correlation functions with predictions of a theoretical model in which the UGRB originates from $\gamma$-ray emitters such as blazars, star-forming galaxies and radio galaxies. We find that the detected signal is consistent with the model prediction.Comment: 11 pages, 24 figures, accepted by MNRA

Intersections of ultracold atomic polarons and nuclear clusters: How is a chart of nuclides modified in dilute neutron matter?

Neutron star observations, as well as experiments on neutron-rich nuclei, used to motivate one to look at degenerate nuclear matter from its extreme, namely, pure neutron matter. As an important next step, impurities and clusters in dilute neutron matter have attracted special attention. In this paper, we review in-medium properties of these objects on the basis of the physics of polarons, which have been recently realized in ultracold atomic experiments. We discuss how such atomic and nuclear systems are related to each other in terms of polarons. In addition to the interdisciplinary understanding of in-medium nuclear clusters, it is shown that the quasiparticle energy of a single proton in neutron matter is associated with the symmetry energy, implying a novel route toward the nuclear equation of state from the neutron-rich side.Comment: 28 pages, 2 figure

頸動脈狭窄に対する自己拡張型ステント留置後フォローアップ時のステント径と内腔の検討

Purpose: We examined postoperative stent and lumen expansions after carotid artery stenting (CAS) in patients with carotid artery stenosis. Furthermore, we investigated factors influencing the stent and lumen expansions in a follow-up period. Subjects: 134 cases (128 patients) who underwent CAS and performed follow-up cerebral angiography 12 months after CAS were enrolled into this study. The stenosis rate based on the stent and lumen diameters on follow-up angiography as a percentage of that immediately after CAS was evaluated. Results: Both the stent and lumen diameters were significantly dilated 12 months after CAS (p <0.001). There were no significant stent-type-related differences in the stent expansion rate. In the symptomatic stenosis group, this expansion rate was significantly higher than in the asymptomatic stenosis group (p = 0.02). With respect to the presence or absence of a high signal intensity on time of flight (TOF) magnetic resonance (MR) images, the stent expansion rate was significantly higher in the high signal intensity group (p = 0.006). In patients with a plaque/sternocleidomastoid muscle signal intensity ratio of ≥1.50 on plaque images, it was significantly higher than in those with a value of <1.50 (p = 0.006). However, there were no significant differences in the lumen expansion rate among the groups. Conclusion: Both the stent and vascular lumen were dilated 12 months after CAS. Plaque fragility influenced the stent expansion rate; however, there were no significant factor-related differences in the vascular lumen expansion rate.博士（医学）・乙第1414号・平成30年3月15日©2017 The Editorial Committee of Journal of Neuroendovascular Therapy. All rights reserved. This is an open access article distributed under the terms of Creative Commons Attribution License(CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0/

Cilostazol minimizes venous ischemic injury in diabetic and normal rats

We evaluated the effects of cilostazol on venous infarction produced by a photothrombotic two-vein occlusion (2VO) model in diabetic and control rats. The cerebral blood flow (CBF) between the occluded veins was measured by laser Doppler flowmetry for 4 hours after 2VO. Infarct size and immunohistochemistry were evaluated 24, 48, 96, and 168 hours after 2VO. Cilostazol was administered 1 hour after 2VO, and thereafter at a continuous oral dose of 60 mg/kg per day. Cilostazol reduced the infarct size, and the number of terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL)-positive apoptotic and B-cell lymphoma 2-associated X protein (Bax)-positive cells, and improved the CBF in control rats. In diabetic rats, cilostazol reduced the infarct size, and the number of TUNEL-positive apoptotic and Bax-positive cells, 96 and 168 hours after 2VO, but did not improve the CBF 4 hours after 2VO. Cilostazol increased the number of B-cell lymphoma 2 (Bcl-2)-positive cells in both strains 48, 96, and 168 hours after 2VO, but did not improve vessel wall thickness or collagen deposits. Cilostazol appeared to limit venous infarcts by improving the penumbral CBF in nondiabetic rats, and inhibited pro-apoptotic changes through Bcl-2 overexpression, without improving the CBF in diabetic rats

Identification Of Novel Biomarker For Human Uterine Leiomyosarcoma

Sarcomas are neoplastic malignancies that typically arise in tissues of mesenchymal origin. The identification of novel molecular mechanisms leading to sarcoma formation and the establishment of new therapies has been hampered by several critical factors. Human uterine leiomyosarcoma (Ut-LMS) develops more frequently in the muscle tissue layer of the uterine body than in the uterine cervix. Although the development of gynecologic tumors is often correlated with the secretion of female hormones; that of human Ut-LMS does not and its risk factors remain unknown. Importantly, a diagnostic biomarker that can distinguish malignant Ut-LMS from benign tumor uterine leiomyoma (LMA) has yet to be established. Therefore the risk factor(s) associated with human Ut-LMS to establish a diagnosis and novel therapeutic method. Proteasome b-ring subunit LMP2/b1i-deficient mice spontaneously develop Ut-LMS, with a disease prevalence of ~40% by 14 months of age. We shown that LMP2/b1i expression was absent in human Ut-LMS, but present in other human uterine mesenchymal tumors including uterine LMA. Therefore, defective-LMP2/b1i expression may be one of the risk factors for human Ut-LMS. LMP2/b1i is a potential diagnostic biomarker for human Ut-LMS, and may be a targeted-molecule for a new therapeutic approach

Acupuncture Improves Sleep Conditions of Minipigs Representing Diurnal Animals through an Anatomically Similar Point to the Acupoint (GV20) Effective for Humans

Acupuncture, an alternative medicine, has been widely applied for people with sleep disturbances; therefore, the effects should be evaluated objectively. Micro-minipigs (MMPigs), the smallest miniature pigs for animal experiments, were used. Acupuncture was performed at two different points: Dafengmen is located on the head and is an anatomically similar point to human-Baihui (GV20), an effective acupoint for sleep disturbances in humans; pig-Baihui is on the back. The procedure was performed as follows: shallow, within 5 mm depth for several seconds; deep, 10–20 mm depth for 20 min. The sleep conditions were evaluated by actigraph, and the amount of catecholamine in pooled urine after acupuncture treatment. MMPigs with deep acupuncture at Dafengmen showed significantly efficient values on actigraph and catecholamine analysis as compared with untreated MMPigs. The effective acupoint for sleep conditions in the porcine model is at an anatomically similar point to humans, rather than the point determined by traditional Chinese medicine